These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
    Author: Kageyama Y, Kihara K, Kamata S, Nagahama K, Yonese J, Fukuda H, Tosaka A, Nagamatsu H, Ishizaka K, Tsujii T, Kitahara S, Morita T, Oshima H.
    Journal: Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388.
    Abstract:
    We retrospectively reviewed pretreatment levels of serum prostate specific antigen (PSA) in 138 newly diagnosed, untreated patients with prostate adenocarcinoma to evaluate the usefulness of serum PSA levels to predict results of radionuclide bone scans. All of the 24 patients with serum PSA levels above 200 ng/ml showed positive bone scans whereas those with serum PSA levels below 10 ng/ml included only three cases (3/51, 5.1%) positive for bone metastasis. All of the three had poorly differentiated adenocarcinoma of the prostate. In conclusion, bone scans may not be necessary in the cases with serum PSA levels less than 10 ng/ml except for those with poorly differentiated adenocarcinoma.
    [Abstract] [Full Text] [Related] [New Search]